Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 785 of 5804
-
Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
Disease control OngoingQUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendeki…
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo therapy may save bladders in bladder cancer patients
Disease control CompletedThe aim of this study is To evaluate the outcomes of patients with muscle invasive bladder cancer managed by trimodal therapy", Neoadjuvant chemotherapy( NAC) followed by Transurethral resection of the bladder tumor then Radiotherapy, for bladder preservation and capability to re…
Phase: NA • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingTo determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Bladder-Sparing chemo trial targets genetic weakness in cancer
Disease control OngoingThis phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cell…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control TerminatedPhase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute M…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Sound waves may help Alzheimer's drugs reach the brain
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of the ExAblate® Model 4000 Type 2.0 system as a tool to open the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Phase: NA • Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Immunotherapy combo shows promise for inoperable esophageal cancer
Disease control CompletedThis study aims to assess the efficacy of durvalumab in combination with radiochemotherapy (FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised unresectable oesophageal cancer. This is a randomized, French national, multicentre, comparative phase…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Own stem cells tested to fight liver scarring in 700 patients
Disease control CompletedThis is a study to assess safety and preliminary clinical activity of treatments of liver cirrhosis in patients with caused by Hepatitis C and Hepatitis B or Nonalcoholic Steatohepatitis of Mesenchymal stem cell. Patients who will be enrolled in the study will be under supervisi…
Phase: PHASE3 • Sponsor: Ukraine Association of Biobank • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
AI and advanced scans aim to predict prostate Cancer's next move
Diagnosis Recruiting nowProstate cancer (PCa) is the most common non-skin malignancy and the third leading cause of cancer death in North American men. The accurately mapped metastatic state is a necessary prerequisite to guiding treatment in practice and in clinical trials. Imaging biomarkers (BMs) can…
Phase: PHASE3 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New hope for leukemia patients: targeted therapy aims to eliminate hidden cancer cells
Disease control Recruiting nowThis phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New heart valve fix device takes on market leader in major trial
Disease control OngoingTo establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functiona…
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has come back (recurrent), or does not respond to treat…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could less radiation be enough for HPV-Positive throat cancer?
Disease control Recruiting nowIn patients with squamous cell carcinoma of the oral cavity, the oropharynx and larynx with local advanced tumors (pathologic stage T3 = pT3) and or lymph node involvement (pN+) postoperative radio - or radiochemotherapy is the standard of care. Postoperative radiochemotherapy is…
Phase: NA • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Wearable patch shocks heart back to rhythm in lab study
Disease control CompletedSingle arm open label evaluation of the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) defibrillation waveform in adult cardiac patients.
Phase: NA • Sponsor: Element Science, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Targeted drug aims to shrink recurrent brain tumors by blocking key growth enzyme
Disease control OngoingThis phase I trial studies the side effects and best dose of savolitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Savolitinib may stop the growth of tumor cells by blocking…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy takes on hard-to-treat skin cancer
Disease control Recruiting nowThis is a phase 2 trial assessing the efficacy of nivolumab, alone or in combination with relatlimab or ipilimumab in treating patients with locally-advanced unresectable or metastatic basal cell carcinoma.
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo may slow advanced prostate cancer
Disease control OngoingThis study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.
Phase: PHASE2, PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control OngoingThis is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New trial aims to stop leukemia relapse after transplant
Disease control OngoingThe current national acute lymphoblastic leukaemia (ALL) trial in adults investigated whether a low (reduced) intensity chemotherapy regimen prior to transplant could improve the outcome of patients with ALL who are over 40 years of age. The results (60% 2 year survival) are very…
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Brain cancer trial tests if precision radiation can beat whole brain therapy for memory preservation
Disease control Recruiting nowStereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole bra…
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC